News

Breakthrough Gene Therapy by Hubble Therapeutics Receives Funding

Breakthrough Gene Therapy by Hubble Therapeutics Receives Funding

Hubble Therapeutics Secures Series A Financing

Hubble Therapeutics LLC, a pioneering biotechnology firm dedicated to addressing pediatric blindness through gene therapy, has successfully closed a $7.3 million Series A funding round. This investment aims to propel their innovative gene therapy candidate, HUB-101, into human clinical trials, marking a significant milestone in the race to restore vision for children with severe retinal diseases.

Innovative Gene Therapy for Severe Eye Disorders

HUB-101 specifically targets two devastating eye disorders: Leber Congenital Amaurosis (LCA16) and Snowflake Vitreoretinal Degeneration (SVD). These conditions, caused by mutations in the KCNJ13 gene, lead to early-onset blindness and are particularly profound in children, often manifesting before the age of five.

The therapy was developed by Dr. Bikash Pattnaik at the University of Wisconsin-Madison. Dr. Pattnaik's work has been instrumental in creating effective treatments for ion channel-related diseases, and HUB-101 embodies hope for affected families. The gene therapy aims to tackle the underlying genetic issues that lead to these debilitating conditions, offering a potential cure rather than just alleviating symptoms.

Research Breakthroughs and Clinical Development

Dr. Pattnaik has invested over 20 years into research that has culminated in curative therapies for various pediatric blindness diseases. "The development of HUB-101 represents a scientific breakthrough, and with it, we see a future filled with hope for patients plagued by these conditions," he expresses enthusiastically. Hubble Therapeutics has also received Rare Pediatric Disease Designation and Orphan Disease Designation from the FDA, showcasing the importance and urgency of this research.

Partnerships to Advance Development

The company is collaborating with Andelyn Biosciences and Virscio to ensure that HUB-101 is developed and manufactured effectively. These partnerships are critical as Hubble Therapeutics anticipates initiating Phase I / II clinical trials in the near future. Such trials will validate the safety and efficacy of their innovative gene therapy.

Support from Investors and Community

Greg Keenan from WARF Ventures highlights the significance of this research, stating, "This groundbreaking research aims to restore vision in patients affected by a rare eye disease that results in blindness. We are excited to continue our support for innovative treatments through our investment in Hubble Therapeutics.”

Commitment to Families Affected by Vision Loss

Jeff Sabados, the Founder and President of Hubble Therapeutics, acknowledges the vital role of the community in this endeavor. "We are immensely grateful for our investors, leading scientists, and patient families who share our vision of restoring sight for those affected by LCA16 and SVD. With this new funding, we aim to enhance our manufacturing capabilities and prepare for clinical trials in the upcoming years, maintaining our commitment to support families worldwide dealing with these challenges," he shares.

About Hubble Therapeutics, LLC

Hubble Therapeutics LLC, often abbreviated as HubbleTx, is at the forefront of developing gene therapies aimed at treating LCA16 and SVD. These conditions cause profound vision loss in both children and adults. HubbleTx combines cutting-edge research from Dr. Pattnaik with a dedicated team focused on improving the lives of those affected by these genetic disorders.

The company aims to leverage gene delivery technology to correct underlying genetic mutations, bringing hope and new possibilities for patients and their families. By engaging in rigorous clinical development and establishing robust collaborations, Hubble Therapeutics works tirelessly to ensure the safety, effectiveness, and accessibility of their future therapies.

Frequently Asked Questions

What is HUB-101 and its purpose?

HUB-101 is a gene therapy being developed by Hubble Therapeutics aimed at curing Leber Congenital Amaurosis (LCA16) and Snowflake Vitreoretinal Degeneration (SVD), severe retinal disorders that cause blindness.

How much funding has Hubble Therapeutics secured?

The company has successfully closed a Series A funding round of $7.3 million, intended to advance its lead candidate into clinical trials.

Who developed HUB-101?

HUB-101 was developed by Dr. Bikash Pattnaik at the University of Wisconsin-Madison, a leading figure in research focused on gene therapies for pediatric blindness.

What designations has HUB-101 received?

HUB-101 has been granted Rare Pediatric Disease Designation and Orphan Disease Designation by the FDA, highlighting its significance in addressing unmet medical needs.

What are the next steps for Hubble Therapeutics?

Hubble Therapeutics plans to enter Phase I / II clinical trials in the near future to demonstrate the safety and efficacy of HUB-101, aiming to restore vision for children affected by LCA16 and SVD.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

SanMar’s Lott Tops Promo Products Power 50 Again in 2026

Updated Category News Views 207

Branded hoodies and logo tumblers rarely make Wall Street’s pulse race, but the numbers behind them deserve a hard look. Jeremy Lott, president and CEO of SanMar, was named the most influential leader in the U.S. promotional-products business for the second consecutive year, taking No. 1 in the 2026 Counselor Power 50 ranking. Awards can be fluff. A repeat win beside...

Continue Reading
Concierto's Azure Push Puts Sovereignty on Display

Updated Category News Views 83

Sovereignty has become the corporate cloud world's favorite hard-edged word. Concierto is taking that word straight onto the Microsoft Ignite 2026 floor, and frankly, it is a sensible place to make the case. The company, part of Trianz, will appear as a Gamechanger Sponsor from November 17 through 20 at San Francisco's Moscone Center, showing its platform at Booth #5435....

Continue Reading
Navan’s Travel Survey Sells Friction as a Business Case

Updated Category News Views 167

A forgotten charger can turn a routine trip into a small mutiny. That is the useful little truth sitting underneath Navan’s new survey of 2,000 Americans who travel for leisure or business. The company is poking at the annoyances people carry from the bedroom packing pile to the jet bridge: forgotten items, rushed airport arrivals, pre-flight drinks, chatty strangers,...

Continue Reading
TRUSTA Targets AI Inference's GPU Memory Squeeze Hard

Updated Category News Views 87

GPU scarcity has turned ordinary server parts into strategic assets, and TRUSTA is leaning right into that uncomfortable fact at SuperComputing 2026. The enterprise-storage brand under ADATA is pitching an upgraded AI Scaler Toolkit built around a fairly sensible premise: companies running large-language-model inference should not have to buy another armful of expensive...

Continue Reading
AMP Tests Debt Market With €1.25 Billion Green Notes

Updated Category News Views 62

Refinancing season has arrived early at Ardagh Metal Packaging, and it is carrying a hefty €1.25 billion price tag. AMP has launched senior secured floating-rate green notes, with proceeds intended to retire two batches of secured debt due in 2028 and leave additional cash on the balance sheet for general corporate purposes, including capital expenditure. This is not...

Continue Reading
Linux Foundation Unveils the Global Fraud Alliance

Updated Category News Views 173

Who would have thought the tech wizards at the Linux Foundation would step up to tackle fraud on a global scale? That's what we've got with their latest play: the Open Financial Trust Alliance (OFTA). Launched at the Singapore FinTech Festival, they've got their sights on connecting the world's disconnected fraud fight. Think of it as a translator for the tangled mess of...

Continue Reading
Sola's 11-Step Push Makes Salon Ownership Less Blind

Updated Category News Views 296

A pristine studio does not pay rent by itself. That is the uncomfortable little truth sitting underneath Sola Salons’ new 11-step roadmap for beauty professionals considering salon-suite ownership. The company is telling stylists, estheticians, nail technicians, massage therapists, and other independent operators to treat the move from commission work to ownership like...

Continue Reading
LASIK Cost Math Deserves a Careful Second Look Today

Updated Category News Views 188

Thirty years of lens purchases can become a nasty tab Contact-lens spending has a funny way of staying invisible until somebody stacks the receipts into one ugly pile. A new cost-of-vision analysis from the surgeon advisory board of BestLASIKSurgeons.com says the average American contact-lens wearer may spend between $22,500 and $30,000 on corrective eyewear across 30...

Continue Reading
Docusign Pushes Contract Data Into ChatGPT Sales Tools

Updated Category News Views 187

Contracts are where sales momentum goes to get lost, buried under old PDFs, approval chains, and somebody’s half-finished CRM note. Docusign’s November 17, 2026 launch is a sensible attempt to drag that information into the place sellers may increasingly spend their working day: ChatGPT for Sales. The company’s new plugin lets a sales rep pull agreement intelligence...

Continue Reading
Paratus on the Move: Seagems JV Under the Microscope

Updated Category News Views 194

What's Cooking with Paratus Energy? Paratus Energy Services Ltd. (ticker: PLSV) just threw us a curveball, announcing a strategic review of its participation in the Seagems joint venture. Now, before you get too jazzed about ticker talk—hold your horses. No one's making any promises about transactions just yet. The decision's still hanging in the balance, even as they...

Continue Reading

Top 5 Most Recently Viewed Articles

Intuitive Machines Secures Major NASA Contract Worth $4.8 Billion

Updated Category News Views 85

Intuitive Machines Secures $4.8 Billion NASA Contract In the ever-changing landscape of space exploration, Intuitive Machines has recently landed a major contract from NASA worth up to $4.82 billion. This agreement aims to improve communication and navigation services for various near-space operations. Stock Prices Soar Following this announcement, Intuitive Machines saw...

Continue Reading
Cilantro Taco Grill Charts Ambitious Expansion Plans for 2025

Updated Category News Views 399

Cilantro Taco Grill Charts Ambitious Expansion Plans for 2025 The rapidly growing Cilantro Taco Grill has exciting plans to expand its footprint beyond the Chicagoland area in 2025, marking a pivotal moment in its journey. They are set to open their doors in new states, a development that signifies their success and commitment to delivering authentic Mexican flavors....

Continue Reading
Nightingale Ice Cream Sandwiches Launch Nationwide at Target

Updated Category News Views 242

Nightingale Ice Cream Sandwiches Launches in Target Stores Fans of ice cream sandwiches are in for a delightful treat as Nightingale Ice Cream Sandwiches is making its debut in select Target stores across the nation. This new venture brings signature chef-crafted flavors to shoppers, offering a taste of joy that has captured hearts and appetites. Your New Favorite Ice...

Continue Reading
Bybit Enhances User Experience with API for Flexible Savings

Updated Category News Views 180

Bybit Enhances User Experience with API for Flexible Savings Bybit, the world's second-largest cryptocurrency exchange by trading volume, has recently made a significant advancement by introducing API access for its On-Chain Earn and Flexible Savings products. This move aims to empower institutional users and developers to seamlessly connect with Bybit's infrastructure,...

Continue Reading
Empowering Indiana's Youth: The Impact of $30 Million Grant

Updated Category News Views 168

Transformative $30 Million Grant Boosts Youth Programs in Indiana An incredible investment from Lilly Endowment Inc. has led to remarkable growth and enhancement of programs across Indiana for Boys & Girls Club organizations. With a significant $30 million grant dedicated to expanding resources, mentorship, and safe spaces, clubs have been empowered to serve more young...

Continue Reading